Virtual Library
Start Your Search
M. Muller
Author of
-
+
P3.02c - Poster Session with Presenters Present (ID 472)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02c-052 - Electronic Nose: An Early Response Biomarker for Anti-PD1 Therapy in Patients with NSCLC (ID 4528)
14:30 - 14:30 | Author(s): M. Muller
- Abstract
Background:
Multiple studies have shown the activity of the anti-PD(L)-1 agents in patients with advanced non-small-cell lung cancer (NSCLC). There is an urgent need to explore biomarkers that predict outcome to anti-PD-1 therapy. The electronic (e) Nose is used to analyse the exhaled gasses and is under development as a diagnostic tool for lung cancer. We aimed to determine the diagnostic accuracy of exhaled breath analysis for responders vs. non-responders to anti-PD-1 treatment in NSCLC patients.
Methods:
Patients with NSCLC who were about to receive Nivolumab, were asked to participate. At baseline and after 6 weeks of treatment exhaled breath analysis took place. Breathprints were collected in duplicate by an e-Nose positioned at the rear end of a pneumotachograph (SpiroNose) (de Vries J Breath Res 2015). RECIST 1.1 criteria were used for response evaluation at three months and six months and reported accordingly: Complete response (CR), Partial response (PR), stable disease (SD), and progressive disease (PD). Data-analysis involved signal processing, environment correction and statistics based on principal component analysis (PCA), followed by discriminant analysis (Matlab2014/SPSS20).
Results:
From August 2015 until April 2016, 56 patients participated in this trial. Forty-two patients had a response evaluation. Principal component 3 and 4 showed a significant difference (p=0.005 and p=0.001) between responders (PR and SD) and non-responders (PD) [Figure A]. Twenty-five patients had a second exhaled breath analysis after 6 weeks. Analysis showed significant differences in PC3 and PC4 between both SD vs. PR (p<0.001) and PD vs. PR (p=0.002) [Figure B].Figure 1
Conclusion:
E-Nose is able to discriminate between responders and non-responders to anti-PD-1 treatment at baseline and 6 weeks follow-up and may therefor be of great value to predict outcome.